Diabetes Mellitus, Type 2  >>  Symlin (pramlintide)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Symlin (pramlintide) / AstraZeneca
NCT00240253: A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

Completed
4
200
US
pramlintide acetate
AstraZeneca
Type 2 Diabetes Mellitus
06/06
06/06
NCT00467649: A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Completed
4
112
US
pramlintide acetate (Symlin), Symlin, rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
AstraZeneca
Type 2 Diabetes Mellitus
04/08
04/08
NCT00950677: The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes

Completed
4
16
US
Byetta (exenatide), Symlin (pramlintide)
Baylor College of Medicine, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes
05/11
05/11

Download Options